| Active substance | vutrisiran |
| Holder | Alnylam Netherlands B.V. |
| Status | Running |
| Indication | treatment of patients with transthyretin-mediated amyloidosis (ATTR amyloidosis) with cardiomyopathy (ATTR-CM) |
| Public documents | Approbation |
| Approbation - Amendment 1 | |
| Information for the patient | |
| Information for the patient - Amendment 1 | |
| Informed consent | |
| Informed consent - Amendment 1 | |
| Last update | 27/10/2025 |